Latest From Genfit SA
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.
Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Genfit SA
- Senior Management
Jean-Francois Mouney, Chmn. & CEO
Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
Dean Hum, PhD, COO
- Contact Info
Phone: (33) 3 20 16 40 00
885 Ave. Eugene Avinee
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.